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SUMMARY: 
    Post‐mitotic, differentiated cells exhibit a variety of characteristics that contrast with those of actively 
growing neoplastic cells, such as expression of cell-cycle inhibitors and differentiation factors.  We 
hypothesized that the gene expression profiles of such cells would reveal the identities of genes that 
function as tumor suppressors. Here we show using in vitro and in vivo studies that the mitochondrial 
protein LACTB is a potent inhibitor of the proliferation of breast cancer cells. Its mechanism of action 
involves alteration of mitochondrial lipid metabolism and differentiation of breast cancer cells. This is 
achieved, at least in part, through reducing the levels of mitochondrial phosphatidylserine decarboxylase 
(PISD), which is involved in the synthesis of mitochondrial phosphatidylethanolamine. These 
observations have uncovered a novel mitochondrial tumor suppressor and demonstrate an interconnection 
between mitochondrial lipid metabolism and the differentiation program of breast cancer cells, thereby 
revealing a new mechanism of tumor suppression.  
 
INTRODUCTION     
    There are currently over 200 different types of cancers, affecting various parts of the body. Cancer can 
arise in almost any organ and any cell type in the body. While the incidence of certain cancers such as 
those of the breast, lung, and colon are high, one seldom hears of a diagnosis of heart cancer or skeletal 
muscle cancer or brain cancer arising from neuronal cells1. Surprisingly, these types of cancers are 
extremely rare or, in some cases, non-existent. This point to the possibility that some tissue-types, and/or 
specific subset of cells within these tissues have already devised ways of countering neoplasia, and as 
such, could provide us with novel insights into the prevention and/or treatment of cancer. A characteristic 
of these “cancer-resistant” cell types (for example, adult myocytes and cardiomyocytes) is that these cells 
are non-proliferative, terminally differentiated2,3, and prefer oxidative phosphorylation over glycolysis as 
their main pathway for energy production. These biological and biochemical characteristics are in stark 
contrast to those of cancer cells, which are by nature proliferative, relatively undifferentiated, and prefer 
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glycolysis to oxidative phosphorylation as their primary mode of ATP generation. This led us to 
hypothesize that the factors that induce or maintain the residence of “cancer-resistant” cells in non-
proliferative, differentiated, oxidative-phosphorylation-preferring could have the characteristics of tumor 
suppressors if expressed in a neoplastic setting. As such, the gene expression profiles of these cells could 
serve as rich sources of novel tumor suppressors, enabling us to uncover novel dependencies and 
vulnerabilities of cancer cells. Indeed, this approach of utilizing the gene expression profiles of 
differentiated muscle cells has allowed us to identify a novel tumor suppressor that operates within 
mitochondria and negatively affects the growth of a variety of tumor cells in vivo and in vitro while 
leaving non-tumorigenic cells minimally affected. Its mechanism of action involves, in significant part, 
alterations of mitochondrial lipid metabolism that are accompanied by differentiation of cancer cells and 
their loss of tumorigenicity. 
 
RESULTS 
Identification of LACTB as a potential tumor suppressor 
    C2C12 mouse muscle progenitors and primary human muscle progenitors were differentiated in vitro 
according to standard protocols (see Methods; Extended Data Fig. 1a-c). Gene expression microarray 
analysis was performed to identify mRNAs that were significantly up-regulated in differentiated post-
mitotic muscle cells of both species relative to their undifferentiated, actively cycling counterparts 
(Extended Data Fig. 1d and Supplementary Table S1). Five genes were chosen for functional validation: 
adenylate cyclase-associated protein 2 (CAP2), beta-lactamase-like protein (LACTB), receptor accessory 
protein 1 (REEP1), PDZ and LIM domain protein 3 (PDLIM3), and small muscle protein X-linked 
(SMPX) (Extended Data Fig. 1e). The cDNA of each was cloned into a doxycycline-inducible Tet-ON 
vector and expressed in a derivative of the MCF7 human breast cancer cell line that carries an introduced 
H‐RAS (G12V) oncogene (MCF7ras)4. Upon doxycycline induction LACTB exerted a profoundly 
negative effect on these cells’ ability to proliferate, SMPX exhibited a modest effect, while no significant 
effect on cell proliferation resulted from over-expression of CAP2, REEP1 or PDLIM3 (Extended Data 
Fig. 1f and Fig. 2a). Consequently, we focused our attention on characterizing the functional role of the 
LACTB protein in cancer cells. LACTB is a mitochondrial protein that is related evolutionarily to 
bacterial penicillin-binding/B-lactamase proteins5,6. Homologs of the LACTB gene are present in the 
genomes of all chordates examined thus far. In mammals LACTB appears to be ubiquitously expressed, 
being most prominent in skeletal muscle, heart and liver5,7. Such evolutionary conservation points to an 
essential, albeit still-unknown, cellular function. LACTB has been found to undergo polymerization into 
filaments within the mitochondrial inter-membrane space, suggesting that this protein might promote 
intra-mitochondrial membrane organization8. LACTB was also suggested to be involved in the regulation 
of complex I of the mitochondrial electron transport chain, since down-regulation of LACTB led to 
decreased activity of this complex9. Through gene co-expression analysis and transgenic mice validation, 
LACTB function has been linked to obesity10 and fatty acid metabolism11, hinting at a possible role in 
regulating cellular metabolic processes. 
    We performed quantitative RT-PCR analyses in order to compare the levels of LACTB mRNA in 
various non-tumorigenic and tumorigenic mammary cell lines. This analysis failed to show any correlation 
between LACTB mRNA expression and the neoplastic cell state (Extended Data Fig. 2a). However, since 
LACTB protein expression has also been shown to be frequently regulated at the post-transcriptional 
level12,13,8, we compared the levels of LACTB protein expression in a panel of normal and neoplastic cells. 
Immunoblot analysis showed a marked reduction of LACTB protein levels in breast cancer cell lines 
relative to non-tumorigenic mammary cells (Fig. 1a). Out of 18 breast cancer cell lines analyzed 15 
showed decreased (albeit never entirely absent) LACTB protein levels, while three cell lines (MCF7ras, 
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SUM159, MDA-MB-231) cells) exhibited LACTB protein levels comparable to those found in non-
tumorigenic cell lines (Fig. 1a). However, further analysis showed that in MCF7ras cells the LACTB 
protein displayed not only mitochondrial but also some punctate non-mitochondrial staining pattern 
(Extended Data Fig. 2b) and the LACTB gene from MCF7ras cells contained the R469K mutation in its 
C-terminus, which is adjacent to one of the three important catalytic/substrate docking domains6. The 
same mutation was found in the endogenous LACTB sequence in SUM159 cells, while the sequence of 
endogenous LACTB in MDA-MB-231 cells harbored no apparent somatic mutations.  
    We proceeded to extend our findings with cell lines to clinical samples by examining the expression of 
LACTB protein in normal human breast tissues (n=120) and in a panel of 714 clinically defined human 
breast cancer samples. While LACTB was expressed in 100% of normal mammary glands analyzed 
(Extended Data Fig. 2c), its expression was significantly down-regulated in 34-42% of breast cancer 
tissues (Fig. 1b, Extended Data Fig. 2d). This down-regulation did not correlate with any particular tumor 
type, grade or size (Fig. 1b and Extended Data Fig. 2e). 
    In order to gauge the cell-biological effects of LACTB expression, we induced LACTB in a panel of 
tumorigenic and non-tumorigenic cell lines and measured cellular proliferation. Since doxycycline has 
been reported to modulate mitochondrial function via its effects on the mitochondrial translation 
machinery14-16, experiments in this study were always performed by adding doxycycline to control cells 
unless otherwise noted. LACTB over-expression decreased the rate of proliferation  in the three breast 
cancer cell lines tested (HMLER, MCF7ras, HCC1806), while proliferation of the three non-tumorigenic 
cell lines (HME, MCF10A, and BJ1) was only minimally affected by LACTB over-expression (Fig. 2a 
and Extended Data Fig. 2f). These results were further confirmed and extended by EdU, Annexin V and 
Ki-67 staining (Fig. 2b, Extended Data Fig. 2g,h) and provided support for the notion that expression of 
LACTB caused responding cells to withdraw from the active cell cycle. Of note, the R469K LACTB 
mutant did not display any negative effect on growth of MCF7ras and HMLER cancer cells (Extended 
Data Fig. 3a) and when wild-type LACTB was expressed in SUM159 and MDA-MB-231 human breast 
cancer cells, it had a negative effect on the growth of SUM159 cells but not on the growth of MDA-MB-
231 cells (Extended Data Fig. 3b). In summary, these and previous results showed that while a substantial 
majority of breast cancer cell lines exhibit down-regulated or mutated LACTB and are negatively affected 
by wild type LACTB induction, there are some breast cancer cell lines (such as MDA-MB-231) that seem 
to be unaffected by induced LACTB expression. 
    We then redirected our attention toward determining whether expression of LACTB in already-formed 
tumors exerted a negative effect on further tumor growth. MCF7ras, HMLER and HCC1806 tumors in 
which LACTB had been induced decreased significantly in size within 2-3 weeks of LACTB induction, 
with some tumors completely disappearing by 4 weeks of LACTB induction (Fig. 2c and Extended Data 
Fig. 3c). Ki-67 staining of tissue sections showed a high proliferation index of the MCF7ras control tumor 
cells (80% positive), while cells expressing LACTB exhibited lower Ki-67 expression (15% positive) 
(Extended Data Fig. 3d). This decrease in proliferation was accompanied by an increase in cleaved 
caspase staining, indicative of apoptosis (Extended Data Fig. 3e). Interestingly, H&E staining of these 
LACTB-exposed tumors showed a staining pattern that was very different from that of control tumors, 
particularly for the HMLER and MCF7ras tumors and to a lesser degree for the HCC1806 tumors. Control 
tumors contained large, poorly differentiated cells with little cytoplasm, relatively little stroma, and small 
areas of central necrosis. In contrast, tumors expressing induced LACTB consisted of large areas of 
necrosis extending throughout the entire tumor, abundant stroma, and residual cancer cells were smaller 
with a more differentiated, epithelial appearance (Extended Data Fig. 3f,d). 
    In order to extend the evidence that LACTB can play an active role in hindering tumorigenesis, we 
employed shRNA to down-regulate LACTB expression in HME cells. Two different LACTB shRNAs (L-
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3 and B-3) were chosen based on their LACTB knockdown efficiencies (86% and 90% respectively; 
Extended Data Fig. 4a). Decreased levels of LACTB in HME cells (termed HME-shLACTB) resulted in a 
2-fold reduction in proliferation relative to unmodified HME cells propagated in parallel, implying that a 
minimal level of LACTB is necessary for efficient proliferation of non-transformed cells (Extended Data 
Fig. 4b). The tumorigenic abilities of the two resulting cell populations (denoted HME-shLACTB-L-3 and 
B-3) were gauged by orthotopic implantation into NOD/SCID hosts.  Both cell populations failed to form 
tumors by 12 weeks post-implantation, indicating that LACTB down-regulation did not suffice, on its 
own, to transform these cells to a tumorigenic state (Extended Data Fig. 4c). Since loss of tumor 
suppressor gene function often requires concomitant expression of an oncogene in order for 
transformation to occur17-20, we tested whether the concomitant knockdown of LACTB and introduction 
of an H‐RAS (G12V) oncogene would make HME cells tumorigenic. Indeed, following orthotopic 
implantation, these cells formed tumors at 6 weeks post-injection, whereas HME cells expressing only the 
introduced H‐RAS (G12V) oncogene failed to form any tumors by 12 weeks post-injection (Extended Data 
Fig. 4c). We also tested whether decreased levels of LACTB caused tumorigenesis when introduced 
together with an alternative oncogene. As seen in Extended Data Fig. 4d-h, tumor growth was also 
observed when down-regulation of LACTB was coupled with up-regulation of an active c‐MYC (T58A) 
oncogene but not when coupled with wild-type human HER2 over-expression. 
 
LACTB mechanism of action 
    Our in vitro experiments revealed that carcinoma cells (HMLER, MCF7ras) that experienced and 
survived forced LACTB expression showed more differentiated morphology characterized by tight 
epithelial cobblestone islands (Extended Data Fig. 5a), increased expression of markers of epithelial 
differentiation (Epcam, CD24) and decreased CD44 expression (Fig. 3a). RT-PCR and 
immunofluorescence analysis confirmed that the cancer stem-cell marker ZEB121,22, as well as several 
mesenchymal markers, were all down-regulated in HMLER cells in which LACTB was induced while 
epithelial markers were upregulated in these cells (Figure 3b and Extended Data Fig. 5b). Forced 
overexpression of LACTB in non-tumorigenic HME cells had no discernible effect on their morphology 
(Extended Data Fig. 5a), the levels of the CD24, CD44 and EPCAM markers (Fig. 3a), and the gene 
expression profile that monitored the mRNA expression levels of mesenchymal, epithelial and cancer 
stem-cell markers (Extended Data Fig. 5b). When injected at limiting dilutions into fat pads of NOD/SCID 
mice, a decrease in tumor formation and tumor weight was seen in the more differentiated HMLER cells 
that experienced chronic LACTB induction relative to control HMLER cells in which LACTB had not 
been induced (Extended Data Fig. 5c). Of note, the in vitro proliferation rates of these two cell lines were 
comparable (Extended Data Fig. 5d). To examine whether LACTB expression can directly lead to the 
induction of epithelial differentiation we used FACS to collect and single-cell clone the more 
mesenchymal, cancer stem cell (CSC)-enriched CD44high/CD24low cells from a population of HMLER-
Tet/ON LACTB cells. LACTB expression was then induced in two of the resulting single-cell clones 
(HMLER-CD44+ cl.1 and cl.2). In both clonal cell populations, those cells in which LACTB was induced 
proliferated slower, formed small epithelial islands within 3-4 days of LACTB expression, and exhibited 
decreased tumorigenesis than the control cells which retained their mesenchymal morphology (Fig. 3c, 
Extended Data Fig. 5e, Supplemental Videos 1-4). Similar effects on epithelial differentiation coupled 
with the loss of tumorsphere-forming and tumor-initiating ability were observed in MCF7ras cells forced 
to express LACTB (Extended Data Fig. 6a-e).  Hence, LACTB was capable of inducing epithelial 
differentiation in carcinoma cells, which was associated with a decrease in their tumor-initiating ability. 
    To discover more direct mechanism(s) of action of LACTB, we concentrated our attention on 
examining several mitochondrial processes upon early time points (within 1 day) of LACTB induction. 
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Such early time points would lead us to the more immediate effects of LACTB on cancer cells, while later 
responses might represent effects that operate further downstream of LACTB expression. As shown in 
Extended Data Fig. 7a-f, we failed to detect any significant changes in ATP or ROS production, 
mitochondrial membrane potential, mitochondrial numbers, localization and structure, or protein levels 
and localization of markers of mitochondrial fusion and fission in MCF7ras cells in which LACTB 
expression had been induced for up to 24 hours. However, when these processes were assessed at later 
time points (3-6 days) they showed significant changes when compared to the control cells (Extended 
Data Fig. 7a-c,f and data not shown). Since bioinformatics and transgenic mice studies have linked 
LACTB to obesity and fatty acid metabolism10,11, we also turned our attention to mitochondrial lipids. LC-
MS analysis of mitochondrial lipids showed significant decrease (30-50%) in the quantities of 
lysophosphatidylethanolamines (LPE) and phosphatidylethanolamines (PE) during the initial induction of 
LACTB expression (24 hours) in the tumorigenic MCF7ras cells but not in non-tumorigenic HME cells 
(Fig. 4a, b; Supplemental Table S2). In order to determine whether the lower levels of LPE and/or PE 
species contributed to LACTB’s negative effect on the proliferation of MCF7ras cells, we supplemented 
the culture medium of LACTB-exposed MCF7ras cell individually with these two lipid classes. Previous 
publications23-25 showed that extracellular LPE, but not PE, can be efficiently transported into 
mitochondria in which the LPE can then be acylated to PE. Supplementation of the growth medium of 
LACTB-induced MCF7ras cancer cells with 20µM LPE (but not with 50µM phosphatidylethanolamine, 
phosphatidylglycerol or lysophosphatidylcholine) increased cell proliferation, thus partially reversing the 
reduction in cell proliferation imposed by LACTB (Fig. 4c). Moreover, EdU staining of MCF7ras cells in 
which LACTB had been induced in the presence of 20µM LPE exhibited a 50% higher proliferative 
capacity relative to control MCF7ras (Extended Data Fig. 8a). LC-MS analysis of mitochondrial LPE 
levels confirmed the increase of LPE levels in mitochondria following supplementation of LPE in culture 
media (Extended Data Fig. 8b). These data provide support for the notion that a significant part of 
LACTB-induced negative proliferative effects on MCF7ras cells is mediated by decreased levels of LPE 
and/or PE. Next, we induced LACTB expression in MCF7ras and HMLER cells that were supplemented 
with 20µM LPE and monitored the level of CD24 as a marker of cellular differentiation. As seen in 
Extended Data Fig. 8c, the level of the CD24-differentiation marker in these cancer cells was not 
increased to that in control cells in which LACTB was induced without LPE addition. These observations 
indicate that supplementation of these cancer cells with LPE upon LACTB expression can counteract the 
differentiation-inducing ability of LACTB and that these two events are interconnected. 
    In order to further identify downstream targets of LACTB’s activity, we hypothesized, that LACTB 
might be modulating the activity of mitochondrial proteins that are involved in phospholipid metabolism, 
notably LPE and PE biology. One such candidate was mitochondrial phosphatidylserine decarboxylase 
(PISD), an inner-mitochondrial-membrane enzyme that converts phosphatidylserine (PS) to PE26. Figure 
5a and Extended Data Fig. 8d show that induced expression of LACTB was associated with strongly 
decreased levels of the PISD protein (by 60-95%) in mitochondria, while other mitochondrial lipid-
metabolizing enzymes were unaffected. This effect was the result of a post-transcriptional event, since 
PISD mRNA levels were not reduced upon LACTB induction (Extended Data Fig. 8e). Kinetic 
experiments, in which doxycycline was added to MCF7ras-Tet/ON-LACTB cells for different lengths of 
time, showed that PISD levels began to decrease at 24 hours of induced LACTB expression (Extended 
Data Fig. 8f). To determine whether LACTB expression directly reduced PISD function in cells, we 
supplemented MCF7ras cells with [3H] serine for up to 6 h and monitored the conversion of 
phosphatidylserine to phosphatidylethanolamine by PISD in both control MCF7ras cells and in MCF7ras 
cell in which LACTB was induced for 2 days. The cells in which LACTB had been induced showed a 
significantly reduced (by 60-80%) production of [3H]PE from [3H]PS, consistent with our previous 
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conclusion that the activity/stability of PISD is influenced by LACTB (Fig. 5b and Extended Data Fig. 
8g). Experiments employing the siRNA targeting of PISD showed that down-regulation of PISD exerted 
similar effects on MCF7ras cell biology as induction of LACTB (Extended Data Fig. 9a-b and as 
previously described25) and that the two effects might operate in the same linear pathway (Extended Data 
Fig. 9c). Of note, R469K LACTB was unable to downregulate PISD (Extended Data Fig. 9d) and LPE/PE 
lipid species (Extended Data Fig. 9e and Supplemental Table S2) and more physiological levels of 
LACTB over-expression (achieved by titrating down our doxycycline levels) in a panel of breast cancer 
cell continued to negatively affect proliferation of cancer cells, resulted in the down-regulation of PISD 
levels (Extended Data Fig. 9f,g), caused changes in the levels of mitochondrial LPE/PE lipids and lead to 
differentiation of HMLER cancer cells (Extended Data Fig. 9h, i). 
    While LACTB is predicted from its structure to be a serine protease, its proteolytic activity has not been 
directly confirmed.  LACTB is inhibited by Z-AAD-CMK27, a known granzyme B inhibitor, which led us 
to predict that it might cleave peptide bonds adjacent to aspartic acid residues. Indeed, LACTB efficiently 
cleaved the fluorogenic peptide Ac-YVAD-AMC, but not the A-AMC or VP-AMC peptides, indicating 
that LACTB possesses proteolytic activity and can cleave peptide bonds adjacent to aspartic acid residues 
(Fig. 5c and Extended Data Fig. 10a). Of note, LACTB R469K mutant also possesses proteolytic activity 
(Extended Data Fig. 10a). This suggests the possibility that even though this mutant still has proteolytic 
activity for the ac-YVAD-AMC peptide in vitro, its’ in vivo specificity might have changed due to the 
posttranslational modification of lysine residue. Our mutational and proliferation studies further 
determined that the proteolytic function of LACTB and its mitochondrial localization were important for 
its tumor-suppressing effect and that the PISD down-regulation in the presence of induced LACTB was 
dependent on the intact catalytic activity of LACTB (Extended Data Fig. 10 b-f). However, in vitro 
incubation of recombinant LACTB with permeabilized mitochondria isolated from MCF7ras failed to 
result in direct degradation of PISD, suggesting that PISD is not a direct substrate of LACTB (Extended 
Data Fig. 10g). However, the absence of an effect of LACTB on PISD protein was difficult to interpret, 
given our inability to know the precise conditions under which these proteins interact in vivo. Fig. 5d 
shows that PISD levels were similarly reduced in response to LACTB induction in tumorigenic HMLER, 
HCC38, HS578t and to a lesser degree HCC1806 cell lines, but not in the SUM149 breast cancer and the 
non-tumorigenic HME and MCF10A mammary cell lines. These data indicate that the decrease in the 
amount of PISD by LACTB might represent a mechanism-of-action of LACTB shared by several, but not 
all, cancer cells and that this reduction in PISD does not occur in the non-tumorigenic cell lines tested. 
The inability of LACTB to down-regulate PISD levels in differentiated non-tumorigenic cells (such as 
HME) explains its inability to negatively affect the proliferation of these cells. This implied, in turn, that 
in tumorigenic cells that had undergone differentiation and loss of tumorigenicity following LACTB 
induction the subsequent induction of LACTB might no longer be able to down-regulate PISD. Indeed, as 
shown in Extended Data Fig. 8f LACTB was unable to down-regulate PISD levels in the already-
differentiated MCF7ras cells that were described in Extended Data Fig. 6a-e further supporting our 
observation that LACTB cannot downregulate PISD in differentiated non-tumorigenic cells, and that the 
actions of LACTB depend on whether it is induced in the context of less-differentiated cancer cell or fully 
differentiated non-tumorigenic cells.  
 
DISCUSSION  
    Our report describes a novel tumor suppressor protein and a novel mechanism of the control of the 
neoplastic state. We show, using in vivo, in vitro and breast cancer tissue studies, that LACTB is a potent 
inhibitor of proliferation of multiple types of breast cancer cells. LACTB has the ability to perturb 
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mitochondrial lipid metabolism and, through such reprogramming, to modulate the differentiation state of 
cancer cells. This is achieved via a novel LACTB-PISD-LPE/PE signaling axis (Extended Data Fig.10h).  
    Mitochondrial phospholipids are important building blocks of mitochondrial membranes and 
perturbation of PE/LPE might influence diverse processes dependent on the proteins within these 
membranes. Since LPE can also serve as a precursor of PE within mitochondria, our work does not 
distinguish between the reduction in PE, LPE, or both as inciting cause(s) for cancer cell differentiation. 
Some reports have previously linked LPE to cell differentiation. For example, LPE-acyltransferase, the 
enzyme responsible for synthesis of PE from LPE, has been reported to have a role in cardiac muscle 
differentiation28. LPE also appears to modulate differentiation of neuronal PC12 cells29. It is plausible, that 
changes in the representation of various mitochondrial phospholipids are required for the differentiation of 
dedifferentiated epithelial cells and that a transient change in the ratio of these mitochondrial 
phospholipids might initiate the process of differentiation. LPE was also reported to act as an inhibitor of 
phospholipase D30. Since phospholipase D has known roles in inducing cellular differentiation31,32, down-
regulating LPE levels through elevated expression of LACTB, might lead to activation of phospholipase D 
and subsequent differentiation.  
    LACTB expression is down-regulated in many breast cancer cell lines and tissues, but is never entirely 
absent. Indeed, available genomic databases also indicate the absence of any significant numbers of bi-
allelic deletions of the LACTB gene. Moreover, our shRNA silencing experiments indicate that strong 
reductions of LACTB leading to the effective absence of this protein negatively affect the growth of 
normal cells, suggesting that minimal levels of LACTB must be retained in order for normal cell 
proliferation to proceed. Together, these observations converge on the notion that LACTB may represent 
an example of tumor suppressor that acts in haploinsufficient way, where loss of the entire protein is 
deleterious for an incipient cell. Intriguingly, our work shows that LACTB preferentially down-regulates 
the level of PISD in certain cancer cells while not displaying this ability in the tested non-tumorigenic 
differentiated cells. Cancer cells differ from normal cells in many biochemical, signaling and regulatory 
pathways, and it will be interesting to examine which regulatory pathways are responsible for this 
differential behavior of LACTB, how do the observed changes in mitochondrial PE and/or LPE influence 
the differentiation state of cancer cells and which signaling pathways are involved in this processes.  
    Our study opens a novel and still-unexplored cancer research area, in which the study of the expression 
profiles of “cancer-resistant” tissues may reveal the identities of hitherto-unidentified tumor-suppressing 
genes. Stated differently, while the vast majority of current cancer research focuses on studying processes 
leading to tumorigenesis in tissues in which cancer regularly occurs, the research field has overlooked the 
other side of the coin - to examine mechanisms, including specific genes, operating in tissues where 
cancers don’t occur. Our study shows that we indeed can learn lessons from such cells and tissues and use 
this knowledge to design new ways of fighting neoplastic cells and the tumors that they form. 
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FIGURE LEGENDS 
 
Figure 1. LACTB down-regulation in cancer cells. (a) Western Blot of endogenous LACTB protein 
levels in a panel of  non-tumorigenic and breast cancer cell lines. Note-LACTB is significantly decreased 
in many breast cancer cell lines, but it is never completely absent. Some levels of LACTB are still present 
upon over-exposure of Western Blot membrane. NT=non-tumorigenic, BC-L=breast cancer luminal, BC-
B=breast cancer basal. (b) Immunohistochemistry of endogenous LACTB protein levels (brown) in a 
panel of 714 clinically-defined human breast cancer samples. Scores 2 & 3 represent LACTB staining that 
was considered normal (not downregulated), while scores 0 & 1 represent LACTB staining that was 
considered downregulated. Lum.A (n=329), lum.B-Her-neg (n=197), lum.B-Her-pos (n=60), Her-pos 
(n=37), trip-neg (n=91). 
 
Figure 2. LACTB-induced effects on proliferation of breast cancer cells. (a) Proliferation rates of cells 
upon LACTB induction. Three independent experiments were performed. (b) DNA synthesis in non-
tumorigenic and tumorigenic cell lines upon LACTB induction. Numbers within the graphs represent 
percentages of gated cells. The experiment was repeated twice. (c) Tumor growth rate upon LACTB 
induction monitored in vivo by whole mouse imaging and tumor measurements. P value < 0.0001 (****) 
is considered very significant. P value>0.05 is non-significant (ns). The experiment was repeated twice. 
 
Figure 3. LACTB-induced effects on cancer cell differentiation. (a) Flow cytometry analysis of marker 
of stem cells (CD44) and markers of epithelial differentiation (CD24, EPCAM) in tumorigenic HMLER 
and non-tumorigenic HME cells upon LACTB induction. Numbers within the graphs represent 
percentages of gated cells. (b) Immunofluorescence staining of HMLER cells upon 2-weeks long LACTB 
induction. Epithelial markers: E-cadherin (white), β-catenin (white), cytokeratin 8 (CK8, white); 
mesenchymal markers: vimentin (white), fibronectin (white), stem cell marker Zeb1 (white) and DAPI 
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(blue). Scale bar 30µm. 2 independent experiments. (c) Growth, morphology and tumorigenicity of two 
single cell clones upon LACTB induction monitored by live time lapse imaging and orthotopic injections. 
Videos of clones n.1 and n.2 are shown in supplemental material. Scale bar 200µm. P value < 0.05 is 
considered significant. 
 
Figure 4. LACTB-induced changes in mitochondrial phospholipids. (a,b) Liquid chromatography-
tandem mass spectrometry analysis of mitochondrial lipid content of LACTB-induced (24-hours of 
induction) vs control HME (a) and MCF7ras (b) cells. The blue perforated line shows the p value of 0.05. 
Signals above this line have significant p<0.05. The experiment was repeated twice. (c) Proliferation rates 
of MCF7ras and MCF7ras-Tet/ON LACTB cells in the presence of doxycycline with or without 
supplementation with lysophosphatidylethanolamine (LPE), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), or lysophosphatidylcholine (LPC)  The experiment was repeated three times. 
Scale bar 200µm. 
 
Figure 5. The role of phosphatidylserine decarboxylase (PISD) in LACTB mechanism. (a) Western 
blot analysis of sub-fractionated MCF7ras cells and MCF7ras-Tet/ON LACTB-expressing cells with 24 
hours of doxycycline treatment. CYT=cytosolic, MITO=mitochondrial fraction. This membrane was also 
used in Extended Data Fig. 7e. The signal for the control antibodies is shared between these two Figures. 
(b) Conversion of phosphatidylserine (PS) to phosphatidylethanolamine (PE) in MCF7ras cells and 
MCF7ras-Tet/ON LACTB treated with doxycycline for 48 h. The experiment was performed in triplicate. 
P value<0.05 is considered significant. (c) Fluorescent absorbance monitored over time as a measure of 
active peptidase activity of LACTB. (d) Western blot analysis of PISD levels in mitochondria isolated 
from a panel of control and Tet/ON LACTB non-tumorigenic (HME and MCF10A) and tumorigenic cell 
lines where doxycycline was added for 24 h. 
 
METHODS 
 
Cell Culture and reagents 
All cells were cultured in a 5% CO2 humidified incubator at 37° C. Cell lines, growth media and sources 
are described in Table S3. Most of the cell lines were purchased commercially from ATCC or Clonetics. 
All cell lines used in this study were verified to be mycoplasma negative and their morphology and growth 
characteristics were compared to published information to ensure their authenticity. For activating 
tetracycline-inducible gene expression, the cells were treated with 0.05-1μg/ml doxycycline hyclate 
(Sigma-Aldrich) in media. Fresh doxycycline was added every 3 days. 
 
Muscle Progenitor Cell and Mesenchymal Stem Cell (MSC) 
C2C12 mouse myoblast cells (ATCC) were cultured in DMEM+15% FBS. For differentiation of C2C12 
cells media were changed to DMEM+2% horse serum. Media was changed every 3 days and 
differentiation occurred around days 4-6. Human progenitor muscle cells (Cell Applications 151-25a) 
were grown and differentiated according to manufacturer’s protocol. 
 
Animals 
All animal experiments were performed with female virgin NOD/SCID mice (non-obese 
diabetic/severe combined immunodeficiency). Mice were 2-4 months of age at time of injections. A 
colony of NOD-SCID mice was maintained in-house. Mice were housed and handled in accordance 
with protocols approved by the Animal Care and Use Committees of the Massachusetts Institute of 
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Technology. Animals were randomized by age and weight. The exclusion criterion of mice from 
experiments was sickness of the animals due to the appearance of spontaneous thymomas that 
sometimes affect NOD/SCID mice. Sample sizes were chosen to reach statistical significance, and 
tumor measurements and data analysis were performed in a blinded fashion. Maximum tumor size 
permitted by our IACUC protocol was 2 cm and these limits were not exceeded in any of our 
experiments. 
 
Viral vectors and infection 
Human LACTB cDNA was purchased from Open Biosystems # MHS1010-98051227.  REEP1 cDNA 
was purchased from Open Biosystems # MHS1010-98051276. CAP2, SMPX and PDLIM3 cDNAs were 
obtained by reverse transcription PCR from differentiated human muscle cells using primers described in 
Table S4. R469K-LACTB cDNA was obtained by reverse transcription PCR from MCF7ras cells using 
primers for LACTB described in Table S4. All cDNAs were then subcloned into the FUW-LPT2 
tetracycline-inducible lentiviral vector (modified from FUW-tetO by Kong-Jie Kah) with puromycin 
resistance gene. dS-LACTB was generated by mutating the serine residue in position 164 to isoleucine 
using primers described in Table S4 and then subcloned into FUW-LPT2 tetracycline-inducible lentiviral 
vector. d1-97-LACTB was generated by PCR using primers described in Table S4; it is starting with 
methionine as amino-acid position number 97. c-MYC T58A was purchased from Addgene #18773. RAS-
IRES-GFP was purchased from Addgene #18780. Human pWPXL-HER2 plasmid was a kind gift from 
Wenjun Guo (Albert Einstein College of Medicine, New York). pMMP-LucNeo, carrying coding 
sequences for luciferase and neomycin phosphotransferase, were obtained from Dr. Segal33. To down-
regulate LACTB expression we used shLACTB L-3 (Open Biosystems # TRCN0000046625) and 
shLACTB B-3 (Broad Institute TRC shRNA library # TRCN0000296726). Both shRNAs are cloned in 
pLKO.1 lentiviral vector with puromycin selection marker. Empty pLKO.1 vector was used as a control. 
For lentiviral infection, cells were seeded at 30% confluency in 10cm dish and transduced 24 hours later 
with virus in the presence of 5 µg/ml polybrene (EMD Millipore # TR-1003-G). Cells were then selected 
by relevant selection marker. 
 
We found the doxycycline-inducible FUW-LPT2 vector to be a little leaky; minimal amounts of cloned 
gene were expressed even in the absence of doxycycline (as judged by RT-PCR analysis). While this 
leakiness never had any physiological significance for short term experiments, keeping such cells for a 
long time in tissue culture might lead to a change in physiology of these cells. Therefore, as a precaution, 
we never kept cell lines transduced with FUW-LPT2+cloned factor in tissue culture for longer than two 
months. After two months, the cell lines were discarded and the new ones were freshly transduced with 
FUW-LPT2+cloned factor vector and selected with proper selection marker.  
 
siRNA and transfection 
Four dsiRNA duplexes against human PISD gene were designed and purchased from Integrated DNA 
Technologies. 
dsiRNA-PISD-1sense: rCrCrArCrCrArUrCrGrUrGrCrUrCrArUrCrUrUrCrGrArGGC 
dsiRNA-PISD-2sense: rCrCrUrArCrArArUrGrArCrUrUrCrArGrCrUrUrCrGrUrGAC 
dsiRNA-PISD-3sense: rCrArArUrCrArGrGrUrGrGrArGrCrUrGrCrCrArCrArCrUGG 
dsiRNA-PISD-4sense: rGrCrArGrGrGrUrGrGrCrUrUrUrGrUrArCrArArGrUrCrAGT 
Premade negative control dsiRNA was purchased from Integrated DNA Technologies (DS NC1, 
180683394). Cells were plated in 10-cm dishes and next day transfected with Lipofectamine 2000 
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(ThermoFisher) according to manufacturer’s protocol. Analyses were performed 48 hours after 
transfection. 
 
Tumor cell injections 
For orthotopic tumor transplantations, cells were resuspended in 20µl of 50%Matrigel and injected into 
mammary fat pads of female NOD-SCID mice. The in vivo doxycycline treatment was administered 
through drinking water containing 2 mg/ml doxycycline and 10 mg/ml sucrose. 
The tumor incidence and weight were measured 2-3 months post injection. For limiting dilution analyses, 
the frequency of cancer stem cells in the cell population being transplanted was calculated using the 
Extreme Limiting Dilution Analysis Program (http://bioinf.wehi.edu.au/software/elda/index.html). 
Regarding Fig. 2c: Control MCF7ras cells and MCF7ras-Tet/ON-LACTB cells were injected (105 cells 
per injection) into fat pads of female NOD/SCID mice. When the tumors reached approximately 10mm in 
diameter doxycycline was added to both groups and tumor growth rate was monitored in vivo by whole 
mouse imaging and tumor measurements. 
 
In vivo mouse imaging 
Bioluminescence imaging of luciferase activity was used to monitor tumor growth with a Xenogen IVIS 
system under 2.5% isoflurane anesthesia at the indicated time points. Imaging of mice was performed by 
injection of D-luciferin (165mg/kg of body weight, intraperitoneal injection; Caliper Life Sciences) 10 
minutes before bioluminescence imaging. Images were analyzed using Living Image Software version 
4.3.1 (Caliper Life Sciences). 
 
Immunofluorescence (tissues, cells) 
Tumors were fixed in 10% neutral buffered formalin overnight and embedded in paraffin for sectioning. 
Sections were cut at 5μm. Tumor sections were deparaffinized in Xylene and antigen retrieval was 
performed in Target Retrieval Solution (Dako # S1700) using a microwave. Background was ten reduced 
using ImmunoStain Blocker Solution (GeneTex # GTX73323) for one hour at room temperature. Sections 
were then blocked with 2% normal horse serum in PBS for one hour at room temperature. Sections were 
incubated with primary antibody at 4⁰C overnight. The type, source and dilution of antibodies are 
described in Table S5. After three washes with PBS, sections were incubated with secondary antibodies 
(AlexaFluor, Invitrogen, 1:500) for one hour at room temperature, washed three times with PBS, and 
mounted on glass microslides (VWR#48312-002) in Prolong gold antifade reagent with DAPI (Life 
Technologies # P36931) and let dry overnight at room temperature in dark. 
 
Cultured cells were seeded on sterilized glass round slides inside 10-cm Petri dishes with cell culture 
media. Once cells reached a sufficient density, glass slides were transferred into individual wells of 6-well 
dish and subsequent processing was done in this format at room temperature unless otherwise stated. Cells 
were washed in PBS, fixed in 10% formalin for 10 minutes, washed once in PBS, permeabilized with 
PBS+0.1% Triton-X for 10 minutes, washed 3x10 minutes in PBS and incubated in 5% horse serum for 1 
hour. Cells were then incubated in specific primary antibodies at 4⁰C overnight, washed three times with 
PBS, then incubated with secondary antibodies for 1 hour at room temperature. After three washes with 
PBS, stained cells were mounted on glass microslides (VWR#48312-002) in Prolong gold antifade reagent 
with DAPI (Life Technologies # P36931) and let dry overnight at room temperature in dark. The type, 
source and dilution of antibodies are described in Table S5. 
Immunostained samples were imaged and analyzed using Zeiss RPI Spinning Disc Confocal microscope 
with MetaMorph Software or Perkin Elmer Spinning Disc Confocal microscope with Volocity software. 
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Electron microscopy 
Cells were fixed in 2.5% gluteraldehyde, 3% paraformaldehyde with 5% sucrose in 0.1M sodium 
cacodylate buffer (pH 7.4), pelleted, and post fixed in 1% OsO4 in veronal-acetate buffer. The cell pellet 
was stained on block overnight with 0.5% uranyl acetate in veronal-acetate buffer (pH6.0), then 
dehydrated and embedded in Embed-812 resin. 
Sections were cut on a Leica Ultracut E microtome with a Diatome diamond knife at a thickness setting of 
50 nm, stained with uranyl acetate, and lead citrate. The sections were examined using a FEI Tecnai spirit 
at 80KV and photographed with an AMT ccd camera. 
 
Western Blot 
Proteins were extracted from cells using RIPA buffer (Sigma Aldrich # R0278) always in the presence of 
Protease (Roche Diagnostics # 11836153001) and Phosphatase (Roche Diagnostics # 04906845001) 
Inhibitors. Human Skeletal Myoblast lysate was purchased from ZenBio # TCE-SKB and lysate from 
differentiated human skeletal myotubes was purchased from ZenBio # TCE-SKM. Approximately 10-
20µg of protein lysate was loaded on the gels. Western blots and transfers were done using standard 
protocols. Horseradish peroxidase-conjugated secondary antibodies were used (Cell Signaling, 1:5000). 
Blots were developed using ECL (Dura or Femto, Thermo Scientific). The type, source and dilution of 
antibodies are described in Table S5. 
 
Western Blot analysis related to [3H]serine labeling of phospholipids was performed by loading sample 
proteins on a 10% gel, then transferring the proteins to polyvinylidene difluoride membranes and blocking 
in 1% milk. The antibodies and their dilutions are described in Table S5. HRP substrate is Luminata Forte 
(Millipore) and images were collected on G:BOX with Syngene software. 
 
Quantitative RT-PCR 
Total RNA was isolated directly from cultured cells using the RNeasy Plus Mini kit (Qiagen # 74136). 
Reverse transcription was performed with High Capacity cDNA Reverse Transcription Kit (Life 
Technologies # 4368814). mRNA levels were measured with gene-specific primers using the SYBR 
Green I master mix (Roche) on a Roche LightCycler 480 system (Roche). Relative expression levels were 
normalized to GAPDH. The PCR primer sequences are listed in Table S4. 
 
Clinical data in human breast tissues 
LACTB expression was studied on 808 patient samples assembled on a tissue microarray as previously 
described34. The study was approved by the ethical committee of the Kanton Zürich under reference 
number KEK-ZH-Nr. 2014-0604. Tumor tissue was immunohistochemically stained using the LACTB 
polyclonal antibody (Proteintech Group, dilution 1:200) on an automated immunostaining platform (Leica 
BOND, Wetzlar, Germany). Immunohistochemical intrinsic subtyping of the cohort was performed as 
previously described35. LACTB expression was analyzed as no expression or lower than in normal tissues 
(scores 0, 1) and normal expression in the luminal or basal compartment (scores 2, 3). Statistical analysis 
was performed with SPSS statistical package version 21 (IBM P-values < 0.05 were considered 
statistically significant).   
 
Flow Cytometry (Edu, Annexin, ROS and Mitochondrial Membrane Potential) 
Cells were trypsinized and filtered through 40µm cell strainers to obtain single cells. Cells were then 
labeled for flow cytometry by 1 hour incubation with dye-conjugated antibodies and washed once in PBS. 
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The list of antibodies, their source and dilution is in Table S5. Samples were sorted on a BD FACSAriaII 
sorter and analyzed using BD FACSDiva Software (BD Biosciences). 
 
Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies # C10424) was used for 
Edu staining according to manufacturer’s protocol. 
ANXN V-PE Apoptosis Detection Kit (BD Biosciences # 559763) was used for annexinV staining 
according to manufacturer’s protocol. 
MitoProbe DiIC 1 (5) Assay Kit (Life Technologies # M34151) was used for mitochondrial membrane 
potential staining according to manufacturer’s protocol. 
DCFDA - Cellular Reactive Oxygen Species Detection Assay Kit (Abcam # ab113851) was used for ROS 
measurement according to manufacturer’s protocol. 
 
ATP measurement 
ATP levels within cells were assessed using the CellTiter-Glo Luminescent Cell Viability Assay  
(Promega # G7572) according to manufacturer’s protocol. 1000-3000 cells were seeded in a flat bottom 
96-well plate. Four replicates were plated for each time point. 
 
Soft agar colony formation assay (tumorspheres) 
Growth in soft agar was performed as described in36. 
 
Subfractionation and Mitochondrial Isolation 
Cells were harvested and mitochondria isolated using the Qproteome Mitochondria Isolation Kit  (Qiagen 
# 37612) for mitochondrial lipid composition analysis or Cell Fractionation Kit (Abcam # ab109719) for 
Western Blot subfractionation experiments. Isolated mitochondria were frozen at -80⁰C. The Cell 
Fractionation Kit was also used for isolating cytosolic fractions. 
Permeabilized Mitochodria: Mitochondria isolated using Qproteome Mitochondria Isolation Kit were 
incubated in hypotonic 100 mM HEPES (pH 7.0-7.6) solution (Sigma # H0887) with or without 150 mM 
NaCl. 
 
Mitochondrial Lipid Extraction 
Frozen mitochondria in eppendorf tubes were thawed on ice, after which 600µl LC/MS grade 100% 
methanol, 300µl LC/MS grade water, 400µl chloroform (without amylenes) were added in this order. 
Samples were vortexed for 10 min at 4⁰C and centrifuged at 13000 RPM for 10 min at 4⁰C. The lower 
lipid-containing layer was then carefully collected and dried for 1 h. Lipid extracts were stored at -80⁰C. 
 
Liquid Chromatography/Mass Spectrometry 
Lipid extracts were separated on an Ascentis Express C18 2.1 x 150 mm 2.7μm column (Sigma-Aldrich, 
St. Louis, MO) connected to a Dionex UltiMate 3000 UPLC system and a QExactive benchtop orbitrap 
mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with a heated electrospray 
ionization (HESI) probe. Dried lipid samples were typically dissolved in 50µl 65:30:5 
acetonitrile:isopropanol:water (v/v/v) and 5µl was injected into the LC/MS, with separate injections for 
positive and negative ionization modes. Mobile phase A in the chromatographic method consisted of 
60:40 water/acetonitrile in 10mM ammonium formate and 0.1% formic acid, and mobile phase B 
consisted of 90:10 isopropanol/acetonitrile, also with 10 mM ammonium formate and 0.1% formic acid.  
The chromatographic gradient was described previously37.  The column oven and autosampler tray were 
held at 55°C and 4°C, respectively.  The MS instrument parameters were as described previously38 and 
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modified by39.  The spray voltage was set to 4.2 kV, and the heated capillary and the HESI were held at 
320°C and 300°C, respectively.  The S-lens RF level was set to 50, and the sheath and auxiliary gas were 
set to 35 and 3 units, respectively.  These conditions were held constant for both positive and negative 
ionization mode acquisitions.  External mass calibration was performed using the standard calibration 
mixture every 7 days. MS spectra of lipids were acquired in full-scan / data-dependent MS2 mode.  For the 
full scan acquisition, the resolution was set to 70,000, the AGC target was 1e6, the maximum integration 
time was 50 msec, and the scan range was m/z = 133.4-2000.  For data-dependent MS2, the top 10 ions in 
each full scan were isolated with a 1.0 Da window, fragmented at stepped normalized collision energy of 
15, 25, and 35 units, and analyzed at a resolution of 17,500 with an AGC target of 2e5 and a maximum 
integration time of 100 msec. The underfill ratio was set to 0.  The selection of the top 10 ions was subject 
to isotopic exclusion, a dynamic exclusion window of 5.0 sec, and an exclusion list of background ions 
based on a solvent blank.   
 
High-throughput identification and relative quantification of lipids was performed separately for positive 
and negative ionization mode data, using LipidSearch software (Thermo Fisher Scientific / Mitsui 
Knowledge Industries) with the default parameters for QExactive Product Search and Alignment.  After 
alignment, raw peak areas for all identified lipids were exported to Excel and filtered according to the 
following pre-determined quality control criteria: Rej ("Reject" parameter calculated by LipidSearch 
software) equal to 0; PQ ("Peak Quality" parameter calculated by LipidSearch software) greater than 0.85; 
CV (standard deviation / average peak area across triplicate injections of a representative [pooled] 
biological sample) below 0.4; R (linear correlation across a three-point dilution series of the representative 
[pooled] biological sample) greater than 0.9.  Typically ~70% of identified lipids passed all four quality 
control criteria.  Raw peak areas of the filtered lipids were added to generate a "total lipid signal" for each 
sample, and individual lipid peak areas were normalized to this total signal as a control for extraction 
efficiency and sample loading.  These normalized lipid abundances from control and LACTB-expressing 
cells were used to calculate fold changes and p-values (Student's t-test, two-tailed, unequal variance) upon 
LACTB expression.  After this calculation, positive and negative ionization mode data were combined to 
generate Fig. 4a and 4b. 
 
Lipid Supplementation 
All lipids were purchased from Avanti Polar Lipids: lysophosphatidylethanolamine (LPE, VWR # 
100123-538), lysophosphatidylcholine (LPC, Avanti Polar Lipids # 830071P), phosphatidylethanolamine 
(PE, VWR # 100127-544), phosphatidylglycerol (PG, VWR # 100123-722). A stock solution (25mM) of 
LPE was prepared as described in40. Stock solutions of LPC, PE and PG (25-100mM) were made by 
dissolving these lipids in chloroform:methanol:water (65:35:8) (v:v) as advised by Avanti Lipids. The 
lipids were replenished every 1 to 3 days. 
 
Time lapse imaging 
Cells were plated sparsely in 12-well plates. If doxycycline was added, it was added 1 h before imaging. 
Cells were monitored with 10x objective using Nikon TE2000 automated inverted microscope with 
incubation enclosure (37⁰C, 5%CO2). MetaMorph acquision software was used to analyze the data. 
 
Recombinant LACTB preparation 
The open-reading frame encoding LACTB was transferred into a Gateway-compatible version of the 
pCLNCX vector (Imgenex) containing C-terminal FLAG and His tags and HEK293T cells were stably 
infected according to the manufacturer’s instructions. The R469K mutant was generated using the 
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QuikChange Site Directed Mutagenesis kit (Stratagene). Cells were grown in DMEM with 10% fetal 
bovine serum at 37°C with 5% CO2.  Infected cells were selected with media containing hygromycin 
(100µg/mL) and grown to 100% confluency (10 × 15 cm plates total). For isolation of LACTB, cells were 
washed two times with PBS and scraped.  Cell pellets were then isolated by centrifugation at 1,400 × g for 
3 min. The pellets were resuspended in RIPA buffer (5mL, Cell Signaling Technology), sonicated, and 
debris was removed by centrifugation at 12,000 × g for 15 min.  LACTB was then captured by incubation 
overnight with 300µL of Anti-FLAG M2 affinity gel (Sigma).  The agarose gel was washed three times 
with PBS (5mL), and LACTB was eluted with 1mL of 150ng/µL solution of 3X FLAG peptide (Sigma) in 
PBS. Protein was then concentrated (and FLAG peptide removed) using an ultra-centrifugal filter unit 
(Amicon, 30kDa cut-off) according to manufacturer’s instructions. Protein concentration was determined 
using a protein assay kit (Bio-Rad). Glycerol was added to a final concentration of 10%, and proteins were 
aliquoted stored at -80 °C until use. 
 
LACTB in vitro substrate assay 
LACTB (15nM final concentration) was added to 96-well black, clear-bottom plate (Costar # 3603) in 
99μL PBS.  Substrates were dissolved in DMSO at 100x indicated concentration (see below) and 1μL was 
added to each well.  Reactions were incubated for 1 h at 25°C while been read on a Spectramax M5 plate 
reader (Molecular Devices) using an excitation wavelength of 380 nm and an emission wavelength of 
460nm.  To test for cleavage of the substrates Ac-YVAD-AMC, A-AMC, and VP-AMC, a final 
concentration of 100µM of each substrate was used.  To assess kinetics of Ac-YVAD-AMC cleavage, 
final substrate concentrations of 100, 33, 11, 3.7, 1.23, 0.41, and 0.14µM were used.  The initial reaction 
velocities for each concentration were fit to a nonlinear regression (Prism software). 
Related to Extended Data Fig. 10g: Recombinant LACTB (0.2 µg) was mixed with perforated 
mitochondria (1 µg) in PBS and incubated at 25⁰C for 2 hours. 
 
[3H]serine labeling of phospholipids  in cells 
MCF7ras and MCF7ras-Tet/ON-LACTB cells were plated on 6-cm dishes and treated with doxycycline 
for 48 hours. Pulse medium (20ml DMEM + 10µl dox + 100µl [3H]serine) was then added for 2, 4 and 6 
h. The [3H-serine] was purchased from Perkin Elmer (250uCi/ 250 µl). Cells were harvested, lysed and 
lipids were extracted and dried. The resuspended lipid extract (50/75µl) was applied to thin-layer 
chromatography plates (Millipore) and separated in the solvent system chloroform:methanol:acetic 
acid:formic acid:water (70:30:12:4:1, v:v). Bands corresponding to standard PS and PE were scraped from 
the plates and radioactivity was measured by scintillation counting after overnight incubation at room 
temperature. The experiment was performed in triplicate. 
Regarding Fig. 5b: Of note, the amount of [3H]PS was not altered by LACTB expression. This is in 
agreement with numerous reports showing that the overall phospholipid levels of cells, including those of 
PS, are very tightly regulated41,42. As such, when PS levels increase, the rate of endogenous PS 
biosynthesis is quickly reduced in a compensatory manner. 
 
Microarray analysis 
The microarrays used were Human and Mouse Agilent 4x44k arrays. Arrays were scanned using an 
Agilent scanner and the data was extracted using Agilent’s Feature Extraction software. Agilent two-color 
arrays were normalized within-array by loess and between-arrays by quantile normalization of average 
intensities (Aquantile), as implemented by the limma package in Bioconductor. Replicate spots were 
averaged and then mean-centered to obtain log ratios. Human and mouse orthologs were obtained from 
Ensembl BioMart and Homologene. 
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Proliferation assay 
Proliferation of cells was assessed using the WST-1 Cell Proliferation Reagent (Roche Diagnostics # 
11644807001) according to manufacturer’s protocol. Cells (1000-3000) were seeded in a flat bottom 96-
well plate. Four replicates were plated for each time point.  
Proliferation of cells was also assessed by seeding cells in 10-cm Petri dishes and trypsinization and 
manual counting of cells, using either haemocytometer or Vi-CELL XR Cell Viability analyzer (Beckman 
Coulter), at indicated time points.   
 
Statistical analysis and Abbreviations 
All the data are presented as the mean ± standard errors of mean (SEM) unless otherwise specified. An 
unpaired two tailed Student’s t-test was used to calculate the p values except as otherwise specified. 
p<0.05 was considered significant. 0.05>p>0.01 (*); 0.01>p>0.001 (**); 0.001>p>0.0001 (***); p<0.0001 
(****). Abbreviations are described in Table S6. 
 
Data Availability 
The microarray dataset was submitted to GEO databank (GSE72916). Source data for Western Blots, 
tumor data and LC-MS experiments are included in Supplementary Information. More detailed data 
and/or protocols are available upon request from the corresponding author. 
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EXTENDED DATA FIGURE LEGENDS 
 
Extended Data Figure 1. Identification of potential tumor suppressors. (a) Light microscope images 
of undifferentiated and differentiated human muscle progenitor cells and mouse C2C12 muscle progenitor 
cells. Scale bar 200µm. (b) Immunofluorescence analysis of mouse C2C12 cells undergoing 
differentiation. Cells were stained with marker of skeletal muscle differentiation α–actinin (green), actin-
staining agent phalloidin (red) and DAPI (blue). Scale bar 30µm. (c) qRT-PCR analysis of expression 
levels of several known tumor suppressors and cell-cycle inhibitors in differentiated human skeletal 
muscle cells confirming that these cells abundantly expressed a variety of tumor suppressors. All the 
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values are relative to undifferentiated cells. GAPDH expression was used as a normalization control. 
Experiment was performed in duplicate. (d) Microarray analysis of undifferentiated (UD) and 
differentiated (D) skeletal muscle cells of human and mouse origin (87 genes, p<0.01, fold change>2). (e) 
qRT-PCR analysis of mRNA levels of five candidate genes. Values are relative to undifferentiated human 
skeletal muscle progenitor cells. GAPDH expression was used as a normalization control. Experiment was 
performed in duplicate. (f) Light microscope images of MCF7ras cells transduced with five doxycycline-
inducible factors in the absence or presence of doxycycline (DOX). Images were taken after 12 days of 
DOX treatment in all groups except for the LACTB cells which were treated for 6 days with DOX. Scale 
bar 200µm. 
 
Extended Data Figure 2. LACTB expression in normal and neoplastic cells. (a) qRT-PCR analysis of 
endogenous LACTB mRNA levels in non-tumorigenic (HME, MCF10A) and neoplastic breast cell lines. 
All values are relative to those in the non-tumorigenic HME cells. GAPDH expression was used as a 
normalization control. Experiment was performed in duplicate. (b) Immunofluorescence staining of 
LACTB in non-tumorigenic (MCF10A) and tumorigenic (MCF7ras) cell lines. Cells were stained with 
mitochondrial marker (green), LACTB (red) and DAPI (blue). The experiment was performed in 
triplicate. Scale bar 30µm. (c) Immunohistochemistry of LACTB protein levels (brown) in normal human 
mammary glands. (d) Immunohistochemistry of endogenous LACTB expression levels (brown) in human 
breast cancer tissue sections. Shown is the amount of LACTB in normal mammary gland and in the 
adjacent neoplastic mammary gland. DCIS=ductal carcinoma in situ; Invasive=invasive carcinoma (red 
circles), M=macrophages (yellow circles); BV=blood vessel. (e) Stratification of low and high levels of 
LACTB in human breast cancer clinical samples of different grade, size and nodal stage. (f) 
Immunoblotting of exogenous LACTB protein in control cells (C) and cells in which LACTB was induced 
by doxycycline (DOX) for 2 days (L). (g) AnnexinV staining in non-tumorigenic (HME) and tumorigenic 
(HMLER, MCF7ras, HCC1806) cell lines upon LACTB induction. Numbers within the graphs represent 
percentages of gated cells. (h) Immunofluorescence analysis of control MCF7ras cells mixed with 
MCF7ras-Tet/ON LACTB cells, in which LACTB was induced for 3 days. Proliferation marker KI-67 
(green), LACTB (red), and DAPI (blue). Note the mutually exclusive KI-67 and LACTB staining in these 
cells. Scale bar 30µm. 
 
Extended Data Figure 3. LACTB-induced effects on proliferation of breast cancer cells. (a) 
Proliferation curves of MCF7ras and HMLER cells over-expressing wild type (wt) and R469K LACTB. 
(b) Proliferation curves of SUM159 and MDA-MB-231 cells upon LACTB induction. (c) Tet/ON LACTB 
cells were injected (105 cells per injection for HCC1806 cells and 106 cells per injection for HMLER cells) 
into fat pads of female NOD/SCID mice. HCC1806-control tumors (n=11), HCC1806+LACTB tumors 
(n=15). When the tumors reached approximately 5mm in diameter, mice were randomly divided into two 
groups and doxycycline was added to one group. In vivo whole mouse images are shown for HCC1806 
tumors. Tumor weight and number of resulting tumors was measured at 3 weeks of doxycycline treatment. 
P values < 0.01 are considered very significant (**). (d) Immunofluorescence analysis of tissue sections of 
control and Tet/ON LACTB MCF7ras tumors with 1 week (Tet/ON LACTB) or two weeks (control and 
Tet/ON LACTB) of doxycycline induction. Tissues were stained with the cell proliferation marker KI-67 
(green), LACTB (red), and DAPI (blue). Note the mutually exclusive effects of LACTB induction on KI-
67 staining in the middle panel. Scale bar 30µm. (e) Immunofluorescence analysis of tissue sections of 
MCF7ras, and MCF7ras-Tet/ON LACTB tumors in which doxycycline (DOX) was added to both groups 
for 1 or 2 weeks. Tissues were stained with antibodies against a marker of apoptosis (cleaved caspase, 
white), and DAPI (blue). Staining was quantified in 8-15 images for each group. “ns” not significant, 
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“*”significant (0.05> p >0.01), “**”very significant (p < 0.01). Scale bar 30µm. (f) H&E staining of 
MCF7ras, HCC1806, and HMLER tumors without or with 2- or 3- weeks of in vivo LACTB induction. 
Scale bar 200µm. 
 
Extended Data Figure 4. Collaboration between down-regulated LACTB and oncogene expression 
in cellular transformation. (a) Immunoblotting of endogenous LACTB protein in HME cells transduced 
with different short hairpin (sh) RNA vectors directed against LACTB. Non-tumorigenic HME cells are 
included as a positive control and tumorigenic HMLER cells as a negative control for LACTB expression. 
Highlighted in red are two LACTB shRNAs chosen for further study. (b) Proliferation rates of HME cells 
transduced with different LACTB-shRNAs. (c,d,e) Tumor incidence was monitored, by in vivo imaging, 
in non-tumorigenic HME cells and in HME cells transduced with shLACTB vectors (L-3 or B-3) with or 
without concominant expression of H-RAS (G12V)(c),  c‐MYC (T58A)(d) or wild type human Her2(e) 
oncogene. Mice were monitored 6, 9 and 12 weeks post-injection. IN=small indolent tumors which 
spontaneously regressed. (f,g) Western Blot analyses of H-Ras, c-myc and wt Her2 expression levels in 
HME-derived cell lines compared to control HME cells. 
 
Extended Data Figure 5. LACTB-induced effects on HMLER differentiation. (a) Light microscope 
images of HMLER and HME cells upon LACTB induction. Scale bar 200µm. (b) qRT-PCR analysis of 
relative mRNA levels of mesenchymal, stem cell and epithelial markers in tumorigenic HMLER and non-
tumorigenic HME cells upon LACTB induction. All the values are relative to control HMLER or HME 
cells in which LACTB was not induced. GAPDH expression was used as a normalization control. (c) 
Frequency of cancer stem cells in control HMLER cells and in differentiated HMLER cells where LACTB 
was induced in vitro for two weeks. Cells were injected in limiting dilutions (1x106, 5x105, 1x105) into fat 
pads of female NOD/SCID mice. 8 weeks post-injection mice were euthanized and tumor frequency and 
tumor diameter calculated and measured. Diameters of tumors arising in 1x106 group are shown. p<0.001 
is considered very significant (***). (d) Proliferation curves of control HMLER cells and differentiated 
HMLER cells. (e) Time lapse images of HMLER-Tet/ON LACTB CD44highCD24low single cell clone 2 
with (+DOX) or without (NO DOX) LACTB induction. Scale bar 200µm. Videos of clones n.1 and n.2 
are shown in supplemental material.  
 
Extended Data Figure 6. LACTB-induced effects on MCF7ras differentiation. (a) Light microscope 
images of control MCF7ras cells and two independently derived MCF7ras bulk populations that survived 
2-weeks long LACTB induction and re-entered their proliferation cycle (LACTB survivor 1 and 2). 
LACTB survivor cells displayed more epithelial-like, differentiated morphology, characterized by tight 
cobblestone epithelial features. Scale bar 200µm. (b) Flow cytometry analysis of levels of the epithelial 
differentiation marker (CD24) in control MCF7ras cells, MCF7ras cells in which LACTB was induced for 
3 days and two independently derived MCF7ras bulk populations that survived 2-weeks long LACTB 
induction and re-entered their proliferation cycle (LACTB survivor 1 and 2). (c) Proliferation curves of 
control MCF7ras cells and two independently derived MCF7ras bulk populations that survived 2-weeks 
long LACTB induction and re-entered their proliferation cycle (LACTB survivor 1 and 2). (d) 
Quantification of in vitro tumor sphere formation of control MCF7ras cells and two independently-derived 
MCF7ras-LACTB survivor populations. Experiment was repeated twice. P<0.01 (**); p<0.001 (***). 
Scale bar 200µm. (e) In vivo tumorigenicity and cancer stem cell frequency of control MCF7ras cells and 
two independently-derived MCF7ras-LACTB survivor populations. Cells were injected at limiting 
dilutions (1x103, 1x102) into fat pads of female NOD/SCID mice and tumor formation was monitored by 
in vivo imaging 8-weeks post-injection. 
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Extended Data Figure 7. LACTB-induced effects on mitochondrial functions. (a) Measurements of 
ATP levels in MCF7ras cells upon LACTB induction. (b) Measurements of ROS levels in MCF7ras cells 
upon LACTB induction. Numbers within the graphs represent percentages of gated cells. (c) 
Measurements of mitochondrial membrane potential, through incorporation of cyanine dye DiIC1(5), by 
flow cytometry in MCF7ras cells upon LACTB induction. Numbers within the graphs represent 
percentages of gated cells. (d) Immunofluorescence analysis of control MCF7ras cells mixed with 
MCF7ras-Tet/ON LACTB cells, where LACTB was induced by addition of doxycycline for 1 day. Cells 
were stained with mitochondrial marker (green), LACTB (red), and DAPI (blue). Mitochondrial signal per 
area in control cells (n=16) and in LACTB-expressing cells (n=17) was calculated by ImageJ software. p 
value > 0.05 is considered not significant (ns). Scale bar 30µm. (e) Western blot analysis of sub-
fractionated control MCF7ras cells and MCF7ras-Tet/ON LACTB-expressing cells with 24 hours of 
doxycycline treatment. CYT=cytosolic, MITO=mitochondrial fraction. Membrane was probed for proteins 
involved in mitochondrial fusion (Opa1, Mfn1, Mfn2), fission (Fis1, Drp1), composition of respiratory 
chain (individual OXPHOS components) and control antibodies: LACTB (to show the proper induction 
and localization of LACTB), actin (cytosolic marker) and COX4 (mitochondrial marker). The membrane 
in this Extended Data Figure was also used in Fig. 5a, where it was probed with different set of antibodies. 
Therefore the signal for the control antibodies is shared between these two Figures. (f) Electron 
microscopy images of mitochondria in control MCF7ras cells or MCF7ras cells where LACTB was 
induced for 1 or 3 days. Scale bar 600nm. 
 
Extended Data Figure 8. The role of PISD in LACTB mechanism-I. (a) Measurement of DNA 
synthesis (through EdU incorporation) in MCF7ras-Tet/ON LACTB cells upon LACTB induction with or 
without supplementation of growth media with 20µM LPE. (b) LC-MS analysis of mitochondrial LPE 
levels upon supplementation of MCF7ras cells with 20µM LPE for 24 hours. (c) Expression levels of 
CD24 differentiation marker in MCF7ras and HMLER cells upon LACTB induction for 6 or 9 days 
respectively, with or without supplementation of growth media with 20µM LPE. (d) Raw western blot 
image showing PISD subcellular location and levels in sub-fractionated MCF7ras and MCF7ras-Tet/ON 
LACTB cells (related to Fig. 6a). Doxycycline was added to both cell lines for 24 h. (e) qRT-PCR analysis 
of mRNA levels of LACTB and PISD in control MCF7ras cells and MCF7ras cells in which LACTB was 
induced for 3 days. GAPDH expression was used as a normalization control. (f) Time course analysis of 
levels of LACTB and PISD in control MCF7ras and MCF7ras-Tet/ON LACTB cells in which LACTB 
was induced by addition of doxycycline (DOX) for the indicated times. In control MCF7ras cells 
doxycycline was added for 3 days. Also shown are the PISD and LACTB levels in MCF7ras-Tet/ON-
LACTB differentiated survivor cell populations 1 and 2 where DOX was added for 24 hours. (g) Related 
to Fig. 5b. MCF7ras cells (C) and MCF7ras-Tet/ON LACTB cells (L) were incubated in the presence of 
doxycycline for 48 h. [3H]serine-containing media was then added for 2, 4 or 6 h. A portion of cell lysate 
was analyzed by immunoblotting to confirm expression of LACTB, down-regulation of PISD and equal 
protein levels in the samples (by calnexin). Western Blot analysis of control MCF7ras cells and MCF7ras 
cells transfected for 48 h with four different PISD-siRNAs. 
 
Extended Data Figure 9. The role of PISD in LACTB mechanism-II. (a) Western Blot analysis of 
control MCF7ras cells and MCF7ras cells transfected for 48 h with four different PISD-siRNAs. (b) The 
proliferation ability of MCF7ras cells transfected with different PISD siRNAs was measured by EdU 
staining using FACS. (c) Control MCF7ras and MCF7ras-Tet/ON-LACTB cells were treated with 
doxycycline for 2 days with or without concominant transfection with 4 different PISD siRNAs. The 
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proliferation ability of the cells was measured by EdU staining using FACS. The rectangle represents the 
gate containing proliferative cells. (d) LACTB and PISD protein levels in mitochondrial fractions of 
control MCF7ras cells and MCF7ras cells with 1 day of wild type LACTB or LACTB R469K induction. 
(e) LC-MS analysis of mitochondrial PE/LPE species (that were shown to be down-regulated upon wild 
type LACTB induction) in control MCF7ras cells and MCF7ras cells where LACTB R469K mutant was 
induced for 24 hours. Values are shown in Supplementary Table S2. (f) Proliferation curves of HMLER, 
and HCC1806 cells upon addition of 0.05μg/ml DOX. (g) LACTB and PISD levels in non-tumorigenic 
HME and tumorigenic HMLER and HCC1806 cells upon addition of 0.05μg/ml DOX. (h) LC-MS 
analysis of mitochondrial PE/LPE/cardiolipin species in control HMLER cells and HMLER cells where 
lower levels of LACTB were induced, through addition of 0.05μg/ml DOX for 24 hours. Values are 
shown in Supplementary Table S2. (i) FACS analysis of CD44 levels in HMLER and HMLER-Tet/ON-
LACTB upon addition of 0.05μg/ml DOX for 14 days.   
 
Extended Data Figure 10. LACTB mutagenesis. (a) Related to Fig. 5c. Velocity of the ac-YVAD-AMC 
enzymatic reaction in relation to substrate concentration for wild type- and R469K mutant LACTB. (b) 
Comparison of amino-acid sequence of wild type (wt) LACTB, dS-LACTB (catalytic site LACTB mutant 
where critical serine residue was replaced by an isoleucine) and d1-97-LACTB (mitochondrial 
localization mutant, as described in ref. 8). Only partial sequence of LACTB is shown. The points of 
mutation of dS- and d1-97 LACTB are highlighted in red and marked by red star symbol. Blue star 
symbol marks the site of R469K mutation in endogenous LACTB from MCF7ras and SUM159 cells. 
Green star symbol marks the site of important substrate docking site in LACTB. (c) Immunofluorescence 
analysis of MCF7ras-Tet/ON dS-LACTB and MCF7ras-Tet/ON d1-97-LACTB cells, where doxycycline 
was added for 24 hours. Cells were stained with mitochondrial marker (green), LACTB (red), and DAPI 
(blue). Scale bar 30µm. (d) Western blot analysis of expression levels of LACTB in control MCF7ras cells 
and MCF7ras-Tet/ON LACTB (wild type, dS, d1-97, dSISK) cells where doxycycline was added for 24 
hours. dSISK-LACTB mutant harbors deletion of 4 amino acid residues in catalytic site of LACTB. The 
expression level of this mutant was unstable therefore we did not include this mutant in our study. (e) 
Proliferation rates of control MCF7ras cells and MCF7ras-Tet/ON LACTB (wt, dS, d1-97) cells upon 
addition of doxycycline for indicated number of days. Pictures were taken at 6 days of doxycycline 
induction. Scale bar 200µm. (f) Western blot analysis of PISD expression in mitochondria isolated from 
MCF7ras and MCF7ras-Tet/ON LACTB (wt and dS) cells where doxycycline was added for 24 hours to 
all groups. (g) Western blot analysis of PISD levels after in vitro incubation of permeabilized 
mitochondria (isolated from MCF7ras cells) with or without addition of recombinant LACTB (isolated 
from HEK293 cells). (h) Graphical Abstract. LACTB induction leads to a change in cancer cell state. As 
such, a proliferative, less differentiated cancer cell turns into a non-tumorigenic differentiated cancer cell 
upon LACTB induction. This is manifested by an initial disappearance of Ki-67 proliferation marker, 
followed by down-regulation of CD44 stem-cell marker and increased expression of CD24 and EPCAM 
differentiated epithelial marker. This is achieved via the ability of LACTB to decrease the protein 
expression levels of mitochondrial PISD enzyme and the subsequent changes in mitochondrial 
phosphatidylethanolamine and/or lyso-phosphatidylethanolamine levels. 
